The ARHGAP32 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting human ARHGAP32 in A-549 lung adenocarcinoma cells. This loss-of-function tool facilitates investigation of ARHGAP32-dependent pathways in a cancer epithelial context.
A-549 cells originate from human lung adenocarcinoma tissue and display adherent epithelial morphology, providing a standard model for lung cancer biology and respiratory epithelium research. These adherent epithelial cells harbor key genetic alterations such as KRAS mutations and are extensively characterized for studies on cancer progression and pharmacodynamics.
ARHGAP32 encodes a GAP that inactivates Rac1 and Cdc42 by accelerating GTP hydrolysis, thereby negatively regulating actin polymerization, cell adhesion, and migration. Upstream regulators include CaMKII and 14-3-3 proteins; interacting partners comprise N-cadherin, ??-catenin, Dishevelled, and Par3. Through these interactions, ARHGAP32 modulates downstream effectors such as PAK, the WAVE complex, Arp2/3, and TCF/LEF transcription factors, integrating Rho GTPase and Wnt/??-catenin signaling. ARHGAP32 activity is regulated by CaMKII-mediated phosphorylation and 14-3-3 binding, which influence its subcellular localization and GAP activity. By interacting with N-cadherin and ??-catenin at adherens junctions and with Dishevelled and Par3 in polarity complexes, ARHGAP32 coordinates actin remodeling with Wnt signal transduction.
Disruption of ARHGAP32 in this adenocarcinoma model enables examination of its role in balancing adhesion and motility, processes central to lung adenocarcinoma invasion and metastasis. The polyclonal nature preserves population-level editing heterogeneity, supporting robust comparative functional studies. This model is valuable for dissecting crosstalk between N-cadherin/??-catenin complexes and Rho GTPase cascades, as ARHGAP32 loss may enhance Rac1/Cdc42 activity, altering actin dynamics and focal adhesions. It may also unveil contributions to epithelial-mesenchymal transition, collective cell migration, and metastatic dissemination, while enabling investigation of Wnt pathway involvement.
Applications include Western blot/RT-qPCR for expression analysis, RNA-seq for transcriptomic profiling, immunofluorescence with phalloidin to visualize F-actin, and migration/invasion assays (Transwell, scratch wound). Mechanistic studies employ co-immunoprecipitation for ??-catenin binding, phospho-signaling analysis (CaMKII), Rho GTPase activation assays (G-LISA), and ??-catenin reporter assays. Drug sensitivity testing can identify therapeutic vulnerabilities. For further assistance, please contact Ascent Research.
